JonesResearch analyst Soumit Roy initiated coverage of Protara Therapeutics (TARA) with a Buy rating and $21 price target The stock is currently trading at cash value, the analyst tells investors in a research note. The firm says Protara has three diverse, late-stage clinical programs, two of which are “fairly de-risked.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARA:
- Protara Therapeutics Reports Q1 2025 Financial Results
- Protara Therapeutics: Buy Rating Affirmed Amid Promising Clinical Data and Strong Financial Position
- Protara Therapeutics’ TARA-002: A Promising Alternative for NMIBC with Strong Efficacy and Safety Profile
- Protara Therapeutics appoints Nicacio as CMO, Williams as CPO
- Protara Therapeutics reports Q1 EPS (29c), consensus (48c)